A PROSPECTIVE, PHASE 3, OPEN-LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH rVWF IN SEVERE VON WILLEBRAND DISEASE
Phase of Trial: Phase III
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Factor VIII (Primary) ; Vonicog alfa (Primary)
- Indications Von Willebrand disease
- Focus Therapeutic Use
- Acronyms rVWF IN PROPHYLAXIS
- Sponsors Baxalta; Shire
- 24 Jan 2018 Planned End Date changed from 1 Mar 2018 to 20 May 2019.
- 24 Jan 2018 Planned primary completion date changed from 1 Mar 2018 to 20 May 2019.
- 24 Jan 2018 Status changed from not yet recruiting to recruiting.